SDZ 280-446: A New Drug to Overcome Cancer Drug Resistance
Author Information
Author(s): F. Loorl, D. Boesch, C. Gaveriaux, B. Jachez, A. Pourtier-Manzanedo, G. Emmer
Primary Institution: Sandoz Pharma Ltd.
Hypothesis
Can SDZ 280-446 effectively reverse multidrug resistance in tumor cells?
Conclusion
SDZ 280-446 significantly enhances the effectiveness of chemotherapy in multidrug-resistant tumor cells.
Supporting Evidence
- SDZ 280-446 was shown to restore drug sensitivity in multidrug-resistant tumor cells in vitro.
- Oral administration of SDZ 280-446 significantly prolonged survival in mice with MDR tumors.
- Combined therapy with vinca alkaloids and SDZ 280-446 was more effective than vinca alkaloids alone.
Takeaway
SDZ 280-446 is a new drug that helps cancer treatments work better by stopping cancer cells from pushing the medicine out.
Methodology
The study involved in vitro tests on various tumor cell lines and in vivo tests on mice with multidrug-resistant tumors.
Limitations
Only a few treatment protocols were tested, and the pharmacokinetics of SDZ 280-446 in humans are not yet established.
Participant Demographics
Mice used in the study were female DBA/2 and B6D2F1 hybrids.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website